•
Mar 31, 2020
InspireMD Q1 2020 Earnings Report
InspireMD's Q1 2020 revenue increased due to CGuard EPS sales, gross profit improved, and operating expenses decreased.
Key Takeaways
InspireMD reported a significant increase in revenue for Q1 2020, driven by strong sales of its CGuard EPS product. The company also improved its gross profit and reduced operating expenses, leading to a lower net loss compared to the same period in the previous year.
Revenue increased by 149.2% to $1,034,000, compared to $415,000 in Q1 2019.
CGuard EPS sales volume increased by 158.2% to $971,000, driven by increased sales and recovery from sterilizer equipment failures in Q1 2019.
Gross profit was $295,000, a significant improvement from a gross loss of $73,000 in Q1 2019.
Net loss decreased to $1,978,000, or $0.43 per share, compared to a net loss of $3,207,000, or $3.82 per share, in Q1 2019.